The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.

wsj.com - 2026-07-14 20:00:00

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.

zacks.com - 2026-07-14 18:45:22

JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.

zacks.com - 2026-07-14 10:56:28

This article was written by Doug Nathman, with research by his team at Trefis.

forbes.com - 2026-07-14 10:30:06

Eli Lilly is the leader in the weight loss drug market -- a market on track to reach almost $100 billion. The company's weight loss drugs have delivered tremendous growth in recent years.

fool.com - 2026-07-14 06:10:00

Eli Lilly (NYSE:LLY | LLY Price Prediction) has whipsawed shareholders in 2026, but the setup heading into the second half looks compelling.

247wallst.com - 2026-07-13 14:00:35

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer's Association International Conference in London. Wall Street weighed in on the stock last week.

benzinga.com - 2026-07-13 08:49:22

Mounjaro and Zepbound combined for $12.8 billion of Lilly's $19.8 billion in first-quarter revenue. Worldwide Mounjaro revenue jumped 125% year over year in the first quarter.

fool.com - 2026-07-13 04:23:00

Lilly's business is booming. However, there is a bear case against the pharma stock.

fool.com - 2026-07-11 04:44:00

Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY | LLY Price Prediction) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker's market capitalization to $1.063 trillion.

247wallst.com - 2026-07-09 14:28:08

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

zacks.com - 2026-07-09 14:06:06

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason.

247wallst.com - 2026-07-09 12:18:28

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

247wallst.com - 2026-07-09 11:35:25

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-07-09 10:46:06

Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Foundayo in new-to-brand prescriptions, driven by superior weight loss efficacy and fewer drug interaction restrictions. Despite setbacks, NVO is advancing late-stage candidates like CagriSema, UBT251, and zenagamtide, aiming to rival Eli Lilly's next-generation assets by the early 2030s.

seekingalpha.com - 2026-07-09 08:46:09

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

fool.com - 2026-07-09 08:15:04

Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disease Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science INDIANAPOLIS, July 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.

prnewswire.com - 2026-07-09 07:30:00

Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.

etftrends.com - 2026-07-08 14:18:25

Eli Lilly leads the high-growth weight loss drug market. The company's weight loss portfolio generated more than $12 billion in revenue in the latest quarter.

fool.com - 2026-07-08 14:10:00

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

marketbeat.com - 2026-07-08 12:36:02

Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.

zacks.com - 2026-07-08 11:11:07

$8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY | LLY Price Prediction) in the first quarter of 2026, a single product, a single quarter, up 125% year over year.

247wallst.com - 2026-07-08 08:42:30

I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing potentially undervalued by my free cash flow model.

seekingalpha.com - 2026-07-08 07:42:40

Eli Lilly's shareholders are in store for even more gains, according to a respected investment bank. The drugmaker is poised to profit from the rapid growth of the global obesity treatment market.

fool.com - 2026-07-07 21:53:37

Drug stocks got hit hard on Monday in what Jim Cramer called a “vicious rotation,” and the selloff looked like the usual crowded-trade unwind.

247wallst.com - 2026-07-07 14:55:13

Eli Lilly and Intuitive Surgical are top players in their respective corners of the healthcare market. Both companies are highly innovative and boast attractive long-term growth opportunities.

fool.com - 2026-07-07 14:15:00

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.

investors.com - 2026-07-07 13:15:09

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

247wallst.com - 2026-07-07 12:30:17

The obesity drug industry is likely a decade-long tailwind for Eli Lilly's business. Foundayo and Retatrutide could cement a decade of growth.

fool.com - 2026-07-07 08:10:00

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.

zacks.com - 2026-07-06 18:46:04

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-06 10:01:06

Eli Lilly (NYSE:LLY | LLY Price Prediction) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare.

247wallst.com - 2026-07-04 14:00:27

Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43.

247wallst.com - 2026-07-01 13:18:32

Innovent Biologics, Inc. and Eli Lilly and Co. (NYSE:LLY) on Tuesday entered into a distribution and promotion agreement for Eli Lilly's breast cancer therapy Verzenios (abemaciclib) in mainland China.

benzinga.com - 2026-07-01 13:09:18

If you sort all the top politicians with a portfolio of above $1 million using their annual gains, who do you expect at the top? Likely Nancy Pelosi, but that's not the case. A Republican Senator named Ashley Moody has gained 310% in the past year using her portfolio. Her portfolio and her (lack of)... New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks

247wallst.com - 2026-07-01 11:50:37

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

proactiveinvestors.com - 2026-06-30 08:19:00

Eli Lilly (LLY) is expanding its China oncology reach through a new commercialization agreement with Innovent Biologics for Verzenios.Under the deal, Innovent w

gurufocus.com - 2026-06-30 07:14:00

Among Nvidia, Apple, Alphabet, Microsoft, Amazon, Taiwan Semi, SpaceX, Broadcom, Tesla, Meta, Micron, Eli Lilly, and Berkshire Hathaway, there are a handful of bargains and pretenders.

fool.com - 2026-06-30 05:06:00

Eli Lilly is leveraging its exceptional cash flow to build an AI-native drug discovery and manufacturing platform, transforming its equity narrative beyond weight loss drugs. LLY's financial momentum is extraordinary, with 2026 revenue guidance of $82–85 billion and non-GAAP EPS of $35.50–37.00, driven by Mounjaro and Zepbound. I view Lilly as an emerging AI company, with proprietary data, AI compute infrastructure, and manufacturing scale creating a compounding R&D ecosystem and operational leverage.

seekingalpha.com - 2026-06-30 04:02:28

Investors rushed to get in on SpaceX's IPO -- and benefit from the company's innovation and growth. Eli Lilly's strength in the high-growth weight loss drug market has supercharged revenue.

fool.com - 2026-06-30 04:02:00

Innovent Biologics ​has entered ‌into an agreement that ​grants ​it sole commercialization ⁠rights for ​Eli Lilly's ​breast cancer drug Verzenios in ​mainland ​China, the Chinese drugmaker ‌said ⁠Tuesday.

reuters.com - 2026-06-30 01:57:56

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China: Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios® (abemaciclib) in mainland China; Lilly will continue to be responsible for manufacturing, supply, and development for the product. Verzenios® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including: (1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.

prnewswire.com - 2026-06-30 00:00:00

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.

zacks.com - 2026-06-29 18:46:16

The U.S. ​Food and ‌Drug Administration has ​selected Eli ​Lilly and Regeneron , ⁠among ​seven companies, ​for a pilot program ​to ​accelerate reviews of ‌new ⁠domestic pharmaceutical manufacturing facilities, CNBC ​reported ​on ⁠Monday citing ​an ​FDA ⁠spokesperson.

reuters.com - 2026-06-29 15:03:21

Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.

cnbc.com - 2026-06-29 14:50:03

LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.

zacks.com - 2026-06-29 12:11:05

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

zacks.com - 2026-06-29 10:31:23

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com - 2026-06-29 08:52:10

Why settle for puny yields when you can buy these monster dividend stocks?

fool.com - 2026-06-29 05:55:00

Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware of the landmark shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo Nordisk.

cnbc.com - 2026-06-28 08:00:01